Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase ProgramAccesswire · Sep 9, 2026
Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.Accesswire · Sep 8, 2026
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19thAccesswire · Aug 13, 2026
Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 RevenueAccesswire · Aug 10, 2026
Aspire Biopharma (NASDAQ:ASBP) Trading Up 10.9% – Time to Buy?Defense World · Aug 4, 2026Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations.